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Introduction {#sec1}
============

Skeletal muscles play a critical role in voluntary movement, and proper regeneration of this tissue after injury can be severely compromised in a variety of contexts including neuromuscular disorders. In vertebrates, muscle progenitors originating from presomitic and cranial mesoderm give rise to "embryonic" or primary myogenesis, necessary to establish the basic muscle pattern, and "fetal" secondary myogenesis, characterized by growth and maturation of the muscle masses and by onset of innervation ([@bib3]). These two waves of myogenesis are mediated by distinct embryonic and fetal myoblasts, respectively, each characterized by differentially expressed genes and properties of the myoblasts as well as the differentiated cells that they produce ([@bib4], [@bib16]). A key regulator of the embryonic and fetal classes is Nuclear Factor I X (*Nfix*), which is abundant in the fetus and almost absent in the embryo ([@bib4], [@bib29]). Nfix drives the transcriptional changes from embryonic to fetal myogenesis by specifically repressing embryonic and activating fetal specific genes ([@bib29]), and its role is partially conserved during evolution ([@bib33]).

Nfix is part of a family of highly conserved DNA-binding proteins that function as transcriptional activators and/or repressors: *Nfia*, *Nfib*, *Nfic*, and *Nfix*. NFI-binding sites are present in the promoter, enhancer and silencer regions of many cellular and viral genes ([@bib19]), and NFI binding motifs were detected in promoters of genes expressed in different organs, such as brain ([@bib2]), lung ([@bib1]), liver ([@bib17]), intestine ([@bib45]), muscle ([@bib41]), connective tissue and skeletal elements ([@bib42]). *Nfix*-null mice are characterized by a reduced body size and inability to fully extend their limbs as well as CNS and skeletal deficits ([@bib6], [@bib9]). NFI binding sites are present in the promoters of the differentiation gene *Myogenin* and muscle-specific phosphofructo-kinase ([@bib8], [@bib10]), and they can form a complex with Myogenin, thus increasing their affinity for muscle-specific genes ([@bib13], [@bib18]).

Another critical regulator of prenatal and postnatal myogenesis is Myostatin, a secreted factor of the TGFβ superfamily that was shown to be a negative regulator of muscle size, where loss-of-function mutations result in a dramatic increase in muscle mass in different species including human ([@bib28], [@bib27], [@bib40]). Although interference of this pathway was reported to lead to functional improvement of dystrophic muscles in mice ([@bib5]), the precise mode of action of this powerful signaling pathway as a potential therapeutic agent for myopathies remains unclear. Notably, the contextual role of Myostatin was highlighted, where in the embryo it regulates the balance between proliferation and differentiation of muscle progenitors ([@bib22]), whereas in the adult, opposing roles in regulating myogenic differentiation have been reported ([@bib20], [@bib44], [@bib25], [@bib43]).

Postnatal myogenesis is assured by satellite cells (SCs) that are located between the basal lamina and the myofiber plasma membrane ([@bib23]). Although they account for less than 5% of total muscle nuclei in adult muscles, they play an indispensible role in the regeneration of adult skeletal muscle ([@bib21], [@bib24], [@bib32], [@bib34], [@bib37]).

Here, we report that absence of Nfix provokes an imbalance in skeletal muscle homeostasis and regeneration. Moreover, we identify Nfix as a regulator of Myostatin, where in vivo silencing of Myostatin in regenerating *Nfix*-null muscles rescues the regeneration defect. These findings have broad implications for the understanding of pathways regulating postnatal myogenesis and regeneration as well as providing insights into the role of Myostatin as a critical regulator of skeletal muscle differentiation.

Results {#sec2}
=======

Altered Skeletal Muscle Phenotype in *Nfix*-Null Mice {#sec2.1}
-----------------------------------------------------

We demonstrated previously that Nfix plays a critical role in the switch from embryonic to fetal myogenesis ([@bib29]). Interestingly, *Nfix*-null mice are characterized by reduced body size and inability to fully extend their limbs, suggesting a possible muscular phenotype ([@bib9]). To explore the role of *Nfix* in adult myogenesis, we examined its expression and observed that both myonuclei and Pax7^+^ SCs express *Nfix* ([Figure 1](#fig1){ref-type="fig"}A). Histological analysis of *Nfix*-null muscles showed a marked reduction in the cross sectional area of myofibers, although general muscle architecture remained normal compared to wild-type littermates ([Figures 1](#fig1){ref-type="fig"}B and 1C). In addition, *Nfix*-null SC-derived myoblasts were able to differentiate in vitro ([Figure S1](#mmc1){ref-type="supplementary-material"}A), with no significant difference in proliferation and apoptosis rates with respect to the wild-type ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). We reported previously that the embryonic marker slow MyHC is negatively regulated by Nfix, through repression of its activator Nfatc4 ([@bib29]). Interestingly, adult muscles lacking Nfix were characterized by an increased expression of slow MyHC, which is evident in both typically slow-twitching muscles (such as the *Soleus*) and fast-twitching muscles (such as the EDL, *Extensor Digitorum Longus*) ([Figure 1](#fig1){ref-type="fig"}D). Notably, *Nfix*-null differentiated SC-derived myotubes in vitro also expressed higher levels of slow MyHC compared to wild-type ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

SC Differentiation and Muscle Regeneration Are Delayed in the Absence of Nfix {#sec2.2}
-----------------------------------------------------------------------------

To assess the role of *Nfix* during regeneration, we first examined single muscle fibers isolated from wild-type and *Nfix*-null mice. Freshly isolated wild-type and *Nfix*-null single fibers had comparable numbers of associated Pax7^+^ SCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and after 24 hr in culture the number of MyoD expressing cells was similar ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Analysis of SC proliferation and percentage of MyoD expression during the first 12 hr in culture revealed no difference between the two groups ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Although no significant alterations in numbers of Pax7^+^ and MyoD^+^ SCs were noted on *Nfix*-null myofibers, immunostaining for MyoD and Myogenin on wild-type and *Nfix*-null myofibers showed a marked reduction in the number of double Myod^+^/Myogenin^+^ cells in absence of Nfix ([Figures 2](#fig2){ref-type="fig"}A and 2B). Notably, this loss of differentiated cells in *Nfix*-null myofibers was more pronounced after 72 hr in culture, suggesting a possible involvement of Nfix during SC differentiation. Interestingly, the reduction in Myogenin^+^ cells was less evident at later stages ([Figure 2](#fig2){ref-type="fig"}B), thus suggesting a delay in muscle differentiation rather than a general block of the differentiation process.

We reasoned that a delay in myogenic differentiation in absence of Nfix could result in an altered regeneration in vivo. We therefore injected the *Tibialis anterior* muscle of wild-type and *Nfix*-null mice with the snake venom cardiotoxin (CTX) to induce muscle regeneration. Following tissue damage, we observed a striking delay in muscle regeneration after injury of *Nfix*-null mice, as observed by persistent expression of developmental MyHC ([@bib7], [@bib38], [@bib39]) (dMHC) expression ([Figures 3](#fig3){ref-type="fig"}A and 3D). In addition, the *Nfix*-null exhibited smaller regenerating myofibers compared to wild-type ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Accordingly, Myogenin expression was delayed and protracted in *Nfix*-null muscles ([Figure 3](#fig3){ref-type="fig"}B), in keeping with our in vitro observations ([Figures 2](#fig2){ref-type="fig"}A and 2B). Nevertheless, in spite of this altered timing, muscle regeneration appeared complete at later time points in the *Nfix*-null (28 days after injury, see [Figure 3](#fig3){ref-type="fig"}A). Interestingly, in *Nfix*-null mice, we observed a marked upregulation of Myostatin, a potent inhibitor of myogenesis, suggesting that this signaling pathway might be involved in the delayed muscle regeneration phenotype ([Figure 3](#fig3){ref-type="fig"}B). This was most evident from day 5 after CTX injection at a time when differentiation has already initiated, and it was accompanied by the upregulation of the Myostatin downstream effector phosphorylated Smad3 (pSmad3), particularly after 7 days ([Figure 3](#fig3){ref-type="fig"}C), suggesting a functional role for Myostatin signaling. These results clearly indicate a role for Nfix in regulating the proper timing of Myostatin expression and, in turn, of muscle regeneration upon injury. Analysis of Myostatin expression in uninjured muscles revealed no difference between wild-type and *Nfix*-null animals (data not shown), suggesting that the upregulation of Myostatin expression specifically occurs as a consequence of muscle injury.

Specific Deletion of Nfix in SCs Recapitulates the Regeneration Defects {#sec2.3}
-----------------------------------------------------------------------

Since Nfix expression is not restricted to SCs, we investigated muscle regeneration after CTX injury in tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice (see [Figure S3](#mmc1){ref-type="supplementary-material"}A) to examine the specific role of Nfix in Pax7^+^ SCs. Tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice were compared with both tamoxifen untreated mice and mice expressing only the *Tg:Pax7-Cre*^*ERT2*^ allele and treated with tamoxifen, as controls. To verify the efficacy of tamoxifen treatment, sections of regenerating mouse muscles from each group were stained for Nfix. In both *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*+/+*^ and tamoxifen untreated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/−*^ mice, all the centrally nucleated myofibers were Nfix^+^, as expected ([Figure S3](#mmc1){ref-type="supplementary-material"}C). In tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice, Nfix expression was completely abolished in regenerating myonuclei, while it was still present in non-muscle nuclei, thereby confirming the specificity of *Tg:Pax7-Cre*^*ERT2*^ deletion ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Efficiency of Nfix deletion was also measured by counting the percentage of Pax7^+^ cells that had excised *Nfix* and was calculated to be 96.2% ± 0.4 ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Notably, tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice showed a delayed regeneration when compared to both tamoxifen untreated floxed mice and tamoxifen treated *Nfix*^+/+^ mice ([Figure 4](#fig4){ref-type="fig"}A). This defective regeneration was evident in tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice at 7 and 14 days post-CTX injection where dMHC expression persisted, and H&E sections revealed the continued presence of necrotic and inflammatory areas ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}E). Further, the analysis of Myogenin clearly showed protracted expression in the tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice, confirming the delay in the regenerative process ([Figure 4](#fig4){ref-type="fig"}B). Finally, the distribution of the cross sectional area of regenerating myofibers in the three groups supports the delayed regeneration phenotype of tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice, mostly evident after 14 days ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These data support the specific function of *Nfix* in SCs for proper timing of Myogenin expression as well as the regeneration process.

Nfix Regulates Myostatin Expression in Differentiating Myoblasts {#sec2.4}
----------------------------------------------------------------

In keeping with the observation that *Nfix*-null mice exhibit delayed muscle regeneration, Myostatin expression was upregulated in the absence of Nfix ([Figure 3](#fig3){ref-type="fig"}B). Since Myostatin is a TGF-β family member with anti-myogenic properties ([@bib11]), its upregulation can explain the delayed regeneration observed in mice lacking Nfix. To address this point, we investigated the possibility that Nfix might directly regulate Myostatin expression in differentiating myoblasts. First, we analyzed Myostatin expression in differentiating SC-derived myoblasts. As shown in [Figure 5](#fig5){ref-type="fig"}A, Nfix acts as a suppressor of Myostatin in differentiating myoblasts, even in absence of the contribution of the myofiber.

For biochemical analysis, we validated this result using the C2C12 myogenic cell line. C2C12 cells were transduced with a lentiviral vector carrying a small hairpin RNA targeting Nfix (shNfix) or a scrambled sequence as a control (scramble). The transduction effectively resulted in the downregulation of *Nfix* expression in shNfix-treated C2C12, as confirmed by western blot ([Figure 5](#fig5){ref-type="fig"}B). Importantly, Myostatin expression was upregulated in Nfix-silenced myotubes starting from day 5, confirming that Nfix was able to downregulate Myostatin expression in differentiating C2C12 myoblasts ([Figure 5](#fig5){ref-type="fig"}C).

Nfix can bind with high affinity to the palindromic consensus sequence TTGGC(N5)GCCAA ([@bib19]), although NFI factors can also bind to hemi-binding sites (a single TTGGC or GCCAA site alone) ([@bib15]) with a lower affinity. In silico analysis using Genomatix Software allowed us to identify hypothetical Nfix hemi-binding sites in the Myostatin promoter that were used to design specific primers. Notably, the identified sites are flanked by putative binding sites for MEF-2, which is a known co-factor of Nfix ([@bib29]).

To assess whether Nfix can bind directly and regulate the Myostatin promoter, we performed a chromatin immunoprecipitation (ChIP) assay on differentiating C2C12. Proliferating C2C12 myoblasts were transduced with a HA-tagged Nfix2 lentiviral vector and then ChIP analysis was performed after 4 days in differentiation medium on the identified Nfix binding domains of Myostatin promoter. As expected, Nfix bound to the Nfatc4 promoter as described previously ([@bib29]), and it was also found to directly bind to Myostatin promoter ([Figure 5](#fig5){ref-type="fig"}D). To determine how Nfix binding affected Myostatin expression, we transduced wild-type and *Nfix*-null SC-derived myoblasts with a Nfix2-HA lentivirus. A significant decrease in Myostatin expression was noted following *Nfix* overexpression, both in wild-type and in *Nfix*-null myoblasts ([Figure 5](#fig5){ref-type="fig"}E), thereby confirming the repressive role of Nfix on *Mstn* expression.

In Vivo Silencing of Myostatin Rescues the Regeneration Delay in *Nfix*-Null Mice {#sec2.5}
---------------------------------------------------------------------------------

From the results indicated above, we predicted that regeneration defects observed in *Nfix*-null mice would be rescued by reducing Myostatin expression. Due to lethality of perinatal mice and difficulties in obtaining viable *Nfix*:*Mstn* double-null mice, we electroporated wild-type and *Nfix*-null regenerating *Tibialis anterior* muscles with control plasmids (scramble) or plasmids carrying an shRNA targeting *Mstn* (shmstn). Initial studies were carried out to verify the correct downregulation of *Mstn* expression after electroporation of the shmstn plasmid both in entire muscles and in re-isolated myoblasts ([Figures S4](#mmc1){ref-type="supplementary-material"}A and [6](#fig6){ref-type="fig"}C). We then electroporated scramble and shmstn plasmids 4 days after muscle injury, to obtain the maximal downregulation of Myostatin around day 6, which corresponds to the temporal window in which Myostatin was upregulated in *Nfix*-null mice ([Figure 3](#fig3){ref-type="fig"}B). Muscles were then isolated and processed at different time points after injury. Remarkably, we obtained a rescue of the regeneration defects of *Nfix*-null mice in muscles treated with the shmstn plasmid, but not with the scramble control vector ([Figure 6](#fig6){ref-type="fig"}A). This was particularly evident at 14 days after muscle injury, as shown by analysis of muscle sections stained for dMHC. The differences observed were even more striking in total muscle section reconstructions ([Figure S4](#mmc1){ref-type="supplementary-material"}C). The analysis of the cross sectional area of regenerating myofibers revealed, as expected, a reduced cross sectional area for *Nfix*-null muscles with respect to wild-type. However, the regenerative delay phenotype was rescued upon Myostatin silencing; shmstn treated *Nfix*-null myofibers were comparable in size to scramble-treated wild-type (WT) fibers at the same time points ([Figure S4](#mmc1){ref-type="supplementary-material"}B). This result highlights Myostatin involvement in the regeneration defects of *Nfix*-null mice, although from this experiment we cannot rule out the contribution of Myostatin to *Nfix*-null myofiber size in resting conditions. Strikingly, the regeneration rescue is supported by quantification of dMHC, whose expression was significantly reduced as a consequence of Myostatin silencing in *Nfix*-null mice ([Figure 6](#fig6){ref-type="fig"}B).

Discussion {#sec3}
==========

Developmental and regenerative myogenesis share common and distinct features. Previous work from our group demonstrated that Nfix is responsible for the transcriptional switch from embryonic to fetal myogenesis during prenatal development ([@bib29]). In the present study, we show that *Nfix* is required for maintaining muscle physiology postnatally and for the proper timing of muscle regeneration, where we report a link between Nfix and *Mstn* expression. Notably, the absence of Nfix leads to a dramatic delay in muscle regeneration in vivo, and this phenotype can be rescued by suppressing *Mstn* expression.

One of the main features that we observed in *Nfix*-null muscles was an altered muscular physiology characterized by a strikingly reduced muscle fiber size and an overexpression of the slow MyHC isoform. As already observed during prenatal development, the ability of Nfix to modulate slow MyHC expression is maintained after birth. Since Nfix plays important roles in brain and CNS development ([@bib6]), those phenotypes might directly or indirectly impact on the muscle phenotypes reported here. However, we show that upregulation of slow MyHC in the absence of Nfix is reproducible in SC-derived myotubes in culture, thus suggesting that the phenotype observed is cell-autonomously dependent on *Nfix* function in muscle. Moreover, ChIP experiments on C2C12 confirmed Nfix binding to Nfatc4 promoter, further suggesting that the mechanism of action is conserved between prenatal and postnatal life.

We also noted delayed differentiation of single fiber-associated myogenic cells that is accompanied by the modulation of *Myogenin* expression. This finding is consistent with the marked delay in regeneration observed in *Nfix*-null mice. Importantly, in addition to the persistent expression of dMyHC and to a delayed expression of *Myogenin* we observed a sustained expression of *Mstn* in injured muscles of *Nfix*-null mice. Myostatin (GDF8) is a potent inhibitor of myogenesis, where a dramatic increase in muscle mass was reported in *Mstn*-null mice ([@bib28]). However, the mode of action of Myostatin remains under debate for both prenatal and postnatal myogenesis ([@bib22]). Here, we show that the increased expression of *Mstn* in both *Nfix* silenced differentiating C2C12 cells and SC-derived myoblasts, as also in *Nfix*-null regenerating muscles, correlates with the delayed differentiation in vitro and in injured muscles. Myostatin is known to inhibit myoblast differentiation through inhibition of SC activation and proliferation ([@bib25], [@bib43]) and through repression of MyoD activity ([@bib20]). Moreover, inhibition of Myostatin is known to accelerate muscle regeneration ([@bib26]), thus supporting a causative relationship between the increase in Myostatin levels that we observed in regenerating *Nfix*-null mice and the delayed regeneration that characterizes them. We note that differences between WT and *Nfix*-null mice are apparent in muscles from day 5 after CTX injection, coinciding with the first difference in *Mstn* expression. Moreover, in vivo silencing of *Mstn* in adult *Nfix*-null muscles resulted in recovery of the correct timing of muscle regeneration after injury, confirming the causative relationship between *Mstn* sustained expression and the delayed regeneration observed in mice lacking *Nfix*. Importantly, the delayed regeneration was observed also in tamoxifen treated *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice, supporting the central role played by Nfix in SCs. Accordingly, isolated SC-derived *Nfix*-null myotubes express higher levels of Myostatin during differentiation and this is reversed upon *Nfix* re-expression. We therefore identified a mechanism of action for Nfix by showing that it can act as a direct regulator of *Mstn*. In light of contradictory reports on the mode of action of Myostatin, it is important to underscore the potentially distinct contextual roles of Myostatin ([@bib22]). Similar to the contextual roles for Notch signaling in adult myogenesis ([@bib30], [@bib31], [@bib35]), recent studies suggest that Myostatin is necessary to regulate to proper balance between proliferation and differentiation of progenitor cells ([@bib14], [@bib22], [@bib25]).

Here, we suggest that *Mstn* regulation is temporally controlled for appropriate muscle differentiation and regeneration. Forced *Mstn* expression or silencing would inevitably led to a complete block in regeneration or to an accelerated differentiation at the expense of the proper muscle physiology.

In summary, this work demonstrates that Nfix acts through an inhibitory mechanism at the *Mstn* promoter in differentiating myoblasts, thereby influencing the commitment of SCs during differentiation and the proper timing of muscle regeneration. The mechanism identified not only broadens our knowledge on the function of Nfix in postnatal skeletal myogenesis, but also contributes to our understanding of molecular mechanisms involved in the regulation of *Mstn*.

Experimental Procedures {#sec4}
=======================

Animal Models {#sec4.1}
-------------

*Nfix*-null mice were generated crossing heterozygous mice obtained from Prof. Richard M. Gronostajski (University of Buffalo) and were always compared to WT littermates or age-matched WT mice. To increase *Nfix*-null mice survival, their food was supplemented with a soft dough chow (Transgenic Dough Diet, Bioserv) starting from postnatal day (P)21, as described ([@bib6]). WT mice used as controls were fed with the same diet. *Tg:Pax7-Cre*^*ERT2*^ mice were described previously ([@bib31]). *Nfix*^*fl*^ mice were obtained from Prof. Richard M. Gronostajski ([@bib6]). Mouse genotyping was performed by PCR (GoTaq DNA Polymerase, Promega) using the primers listed in [Table S1](#mmc1){ref-type="supplementary-material"}. For muscle regeneration, 20 μl of 100 μM CTX from *Naja mossambica* (Sigma-Aldrich) were injected in the *Tibialis anterior* of 2-month-old mice. Induction of *Nfix* deletion in *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ was performed by multiple tamoxifen injections. Starting from P18, mice received three subcutaneous injections (one every 24 hr for 3 days) of 50 μg tamoxifen (20 mg/ml) per gram of mouse. At 1 week before CTX, mice were subjected to an intraperitoneal injection of 25 mg/ml tamoxifen (250 μγ per gram of mouse). Starting from the day after, mice were fed with a specific tamoxifen enriched or control diet (Harlan). A detailed scheme of tamoxifen treatment is described in [Figure S3](#mmc1){ref-type="supplementary-material"}A.

Mice were kept in pathogen-free conditions and all procedures were conformed to Italian law (D. Lgs n° 2014/26, implementation of the 2010/63/UE) and approved by the University of Milan Animal Welfare Body and by the Italian Minister of Health.

Measurement of Myofiber Cross Sectional Area {#sec4.2}
--------------------------------------------

Cross sectional area of the myofibers was calculated on section images obtained from *Tibialis anterior* muscles using ImageJ.

Cell Culture {#sec4.3}
------------

C2C12 cells (ATCC) were cultured at 37°C, 5% CO~2~ in DMEM (Lonza) plus 20% fetal bovine serum (FBS) (Lonza), 2 mM L-Glutamine (Sigma-Aldrich), and 1% Penicillin/Streptomycin (Euroclone). Differentiation was induced plating 1.5 × 10^5^ cells in 35 mm petri dishes with DMEM, 2% horse serum (Lonza), 2 mM L-Glutamine and 1% Penicillin/Streptomycin.

SC Isolation and Culture {#sec4.4}
------------------------

SCs (myoblasts) were isolated from WT and *Nfix*-null mice at P7--P10. Forelimb, hindlimb, and diaphragm muscles were dissected, mechanically cut, and enzymatically digested at 37°C under constant shaking with a solution containing Collagenase I (100 μg/ml, Sigma-Aldrich), Dispase (500 μg/ml, Gibco), and DNaseI (100 μg/ml, Roche) in PBS (Sigma-Aldrich). Undigested tissue was precipitated for 5 min, and the supernatant was centrifuged for 5 min at 1,200 *g*. The cell pellet was resuspended in DMEM plus 10% FBS, 3% chick embryo extract, 2 mM L-Glutamine, 1% Penicillin/Streptomycin and preplated in 150 mm petri dishes for 1 hr. After pre-plating, the non-adherent, myoblast enriched population was collected and plated in collagen coated (Collagen from calf skin, Sigma-Aldrich) 90 mm petri dishes at a density of 15,000 cells per petri. After a few days in proliferation, the myoblasts were eventually plated at high density (250,000 cells in 35 mm dishes) in differentiation medium (DMEM, 5% horse serum, 2 mM L-Glutamine, and 1% Penicillin/Streptomycin).

For cell sorting experiments, tissues were processed similarly, and then cells were blocked with 10% donkey serum (Sigma-Aldrich) in PBS for 15 min at room temperature (RT). The cells were incubated 30 min on ice with primary antibody detecting SM/C-2.6 antigen, biotinylated, 1:200 ([@bib12]). After two washes, cells were incubated with Streptavidin-APC (BD Pharmingen, 1:500) and CD45-FITC (Rat Anti-Mouse, 30-F11, BD Pharmingen, 1:100), 20 min on ice. The cells were washed again and sorted with a MoFlo XDP cell sorter (Beckman Coulter) based on positivity for SM/C-2.6 antigen and negativity for CD45.

BrdU Incorporation {#sec4.5}
------------------

For BrdU incorporation, 3 × 10^4^ SC-derived myoblasts were plated in 35 mm petri dishes. The cells were exposed for 1 hr to 50 μm BrdU (Amersham). The cells were then fixed with 95% EtOH-5% acetic acid (VWR) for 20 min at RT, incubated with PBS-1.5 M HCl (VWR) for 10 min at RT, washed twice with PBS, and permeabilized with 0.2% Triton in PBS. Primary antibody (1:100, anti-Bromo-deoxyuridine clone BU-1, Amersham) was incubated for 1 hr at 4°C. After four washes, secondary antibody (1:500) was incubated with Hoechst for 40 min at RT. The cells were washed twice with PBS before mounting.

ELISA Assay for Caspase 9 Concentration {#sec4.6}
---------------------------------------

Measurement of the apoptosis rate was performed with an ELISA kit for the detection of mouse Caspase-9 concentration (Cusabio Biotech), according to manufacturer's instructions. Data were acquired with a spectrophotometer (wavelength 450 nm, Tecan). Calculation of results was performed using Curve Expert software.

Single Fiber Isolation and Culture {#sec4.7}
----------------------------------

Single muscle fibers were isolated from gastrocnemius and quadriceps muscles as previously described ([@bib36]). In brief, muscles were enzymatically dissociated with 0.2% Collagenase I (Sigma-Aldrich) in DMEM for 30 min at 37°C with constant rolling. Single fibers were isolated under a stereomicroscope by gently passing through fire-polished Pasteur pipettes with different sized apertures. Purified single fibers were transferred in new plates with SC growth medium, cultured at 37°C, 5% CO~2~, and fixed for staining with 4% paraformaldehyde every 24 hr from 0 to 96 hr. EdU incorporation and staining were performed using the Click-iT EdU Alexa Fluor 594 Imaging Kit (Life Technologies), according to manufacturer's instruction.

Lentiviral Transduction {#sec4.8}
-----------------------

C2C12 myoblasts were transduced with a lentivirus carrying a scrambled sequence or a shNfix. Transduction was performed in suspension (in DMEM 20% FBS), at a MOI of 100 and in the presence of Polybrene (8 μg/ml, Sigma-Aldrich). After overnight (O/N) incubation, the medium was changed, and cells were treated with puromycin (2 μg/ml, Sigma-Aldrich). SC-derived myoblasts and C2C12 used for ChIP experiments were transduced with a lentiviral vector carrying a control sequence or a Nfix2-HA-tagged isoform, described in [@bib29].

Immunofluorescence and Histology {#sec4.9}
--------------------------------

Muscles were isolated from tendon to tendon, rapidly passed in liquid nitrogen-cooled isopentane (VWR) for 1 min, then in liquid nitrogen for 2 min, and left at −80°C until processed. There were 7 μm sections that were cut with a cryostat (Leica) on positively charged glass slides (Superfrost Plus, Thermo Scientific). Muscle sections were stained with H&E (Sigma-Aldrich) according to standard protocols. For immunofluorescence analysis, cells or sections were fixed for 10 min with 4% paraformaldehyde in PBS at 4°C (apart from staining for dMHC that do not require fixation). Samples were then permeabilized with 1% BSA (Sigma-Aldrich)-0.2% Triton X-100 (Sigma-Aldrich) in PBS for 30 min and blocked with 10% goat serum (Sigma-Aldrich) in PBS for 30 min at RT. Primary antibodies were incubated O/N at 4°C in PBS. After two washes with PBS-1% BSA-0.2%Triton, samples were incubated with secondary antibodies (1:500, Jackson Laboratory. Fluorochromes used: 488, 649, 594, and 546) and Hoechst (1:500, Sigma-Aldrich) in PBS for 45 min at RT, washed twice with PBS-0.2% Triton and mounted with Fluorescence Mounting Medium (Dako).

Immunofluorescences on single fibers were performed in suspension. Single myofibers were collected in 1.5 ml tubes and fixed for 10 min with 4% paraformaldehyde in PBS at 4°C. Fixed myofibers were treated with PBS-1% Triton-10% goat serum for 30 min at RT. Primary antibodies were incubated O/N in PBS-1% goat serum. After two washes with a solution containing 1% BSA in PBS, single myofibers were incubated with secondary antibodies and Hoechst in PBS for 1 hr at RT, washed twice with PBS-1% BSA, and mounted on slides.

Images were acquired at RT using a Leica-DMI6000B fluorescence microscope equipped with 10× and 20× magnification objectives. Leica DFC365FX or DFC400 cameras were used for image capture. The Leica Application Suite software was used for acquisition. Single channel pictures were merged using Photoshop. The following primary antibodies and dilutions were used: rabbit anti-Nfix (1:200, Novus Biologicals); chicken anti-laminin (1:500, Abcam); rabbit anti-laminin (1:300, Sigma-Aldrich); mouse anti Pax7 (1:2, DSHB); mouse anti-total MyHC (MF20) (1:2, DSHB); chicken anti-β-gal (1:500, Abcam); mouse anti-dMHC, which detects the Myh3 isoform (1:40, Monosan); rabbit anti-MyoD (C-20) (1:60, Santa Cruz Biotechnology); and mouse anti-Myogenin (1:3, DSHB).

RNA Extraction, RT-, and Real-Time qPCR {#sec4.10}
---------------------------------------

Total RNA from cultured cells was extracted using the NucleoSpin kits RNA XS and II (Macherey-Nagel). Isolation of total RNA from muscles was performed with TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. RNA was quantified using a NanoPhotometer (Implen). There was 1 μg of total RNA for each sample that was retrotranscribed with the iScript Reverse Transcription Supermix for RT-quantitative (q)PCR (Bio-Rad) in a total volume of 20 μl. For qRT PCR, cDNA was diluted 1:10 and 5 μl of the diluted cDNA was loaded in a total volume of 20 μl (iTaq Universal, Bio-Rad). Primers used are listed in [Table S2](#mmc1){ref-type="supplementary-material"}. The relative quantification of gene expression was determined by comparative CT method, and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

ChIP Assay {#sec4.11}
----------

For ChIP, 3.5 × 10^6^ scramble C2C12 myoblasts per antibody were plated. The cells were maintained in culture for 1 day in DMEM, 20% FBS, and then induced to differentiate with DMEM, 2% horse serum, at a density of 1.5 × 10^6^ cells in 90 mm petri dishes. Crosslink was performed at day 4 in differentiation with 1% formaldehyde (Sigma-Aldrich) in DMEM for 10 min. Crosslink was blocked with 0.125 M Glycine (Sigma-Aldrich) in PBS for 10 min while shaking. After two washes with PBS, cells were scraped with PBS containing protease inhibitors and phenylmethanesulfonyl fluoride (PMSF) and centrifuged for 15 min at 1,500 *g* at 4°C. The cell pellet was dounced 20 times in a 7 ml pestle in swelling buffer, then centrifuged for 10 min at 5,000 *g* at 4°C, and the nuclei pellet was sonicated with a Bioruptor Sonicator (Diagenode) for 15 min, with repeated cycles of 15 s of sonication and 15 s of resting. Samples were finally centrifuged for 10 min at 12,000 *g* at 4°C, and chromatin-enriched supernatant was used in the following passages. Chromatin was pre-cleared for 2 hr with Protein G Sepharose (PrG, 15 μl per sample) (Amersham) and rabbit serum (2.5 μl per sample) and for 2 hr with PrG previously blocked with BSA (10 μg/ml) and Salmon Sperm (1 μg/ml) (Sigma-Aldrich) on a rotating platform at 4°C. Chromatin was than incubated O/N with primary antibodies. The day after, immunocomplexes were precipitated by addition of blocked PrG for 3 hr on rotating platform at 4°C, then centrifuged for 2 min at 12,000 *g* at 4°C. Samples were then repeatedly washed and the antibody-protein-DNA complexes were eluted twice for 10 min at 65°C. Eluted samples were incubated O/N at 65°C with 10 μg RNase (Sigma-Aldrich) and 200 mM NaCl (Sigma-Aldrich) to reverse crosslinks. Finally, DNA was treated with Proteinase K (Sigma-Aldrich) (20 μg per sample) for 3 hr at 50°C and then extracted with phenol-chloroform. Obtained DNA samples were analyzed with qPCR and results were plotted as fold enrichment with respect to the IgG sample. Primers used are listed in [Table S3](#mmc1){ref-type="supplementary-material"}.

There were 5 μg of the following primary antibodies that were used: rabbit anti-HA-probe (Y-11, Santa Cruz Biotechnology); normal rabbit IgG (Santa Cruz Biotechnology).

Western Blot {#sec4.12}
------------

Total protein extracts were obtained from cells or homogenized tissues, lysed with RIPA or Tissue extraction buffer plus protease and phosphatase inhibitors for 30 min on ice. Samples were then centrifuged 10 min at 12,000 x *g* at 4°C, and the supernatant transferred into a new tube and quantified using the DC Protein Assay (Bio-Rad). There were 30 μg of total protein extracts that were loaded on a 7%--12% SDS (Sigma-Aldrich) acrylamide gel (Sigma-Aldrich) and blotted to a nitrocellulose membrane (Whatman, Protran Nitrocellulose Transfer Membrane). After 1 hr of blocking in milk, primary antibodies were incubated O/N. Blots were then washed and incubated with secondary antibodies (1:10,000, IgG-HRP, Bio-Rad) for 40 min at RT and washed again. Finally, bands were revealed with ECL detection reagent (Amersham) and exposed to an X-ray film (Hyperfilm ECL, Amersham). In some cases, blots were acquired using the Chemidoc software (Bio-Rad).

The following primary antibodies and dilutions were used: rabbit anti-Nfix (1:5,000, Geneka Biotechnology); mouse anti-β-tubulin (1:5,000, Covance); mouse anti-slow MyHC (Bad5, 1:2, DSHB); mouse anti-total MyHC (MF20, 1:5, DSHB); mouse anti-Myogenin (IF5D, 1:3, DSHB); rabbit anti-Myostatin (1:500, Millipore); mouse anti-GAPDH (1:5,000, Sigma-Aldrich); rabbit anti-Smad3 (1:1,000, Abcam); rabbit anti-pSmad3 (1:1,000, Abcam).

In Vivo Electroporation {#sec4.13}
-----------------------

In vivo electroporation was performed 4 days after CTX injection. WT and *Nfix*-null mice were anesthetized and 40 μg of control (scramble, Sigma-Aldrich), or shmstn (Sigma-Aldrich) plasmids were injected in a total volume of 20 μl in *Tibialis anterior* muscles. Muscles were then immediately electroporated using a pulse generator (ECM 830, BTX) equipped with 5 mm needle electrodes to generate 100 V pulses, with a fixed duration of 20 ms and an interval of 200 ms between the pulses.

Statistical Analysis {#sec4.14}
--------------------

All data are expressed as mean ± SD. Data were graphed using GraphPad Prism and analyzed with the two-tailed unpaired Student's t test. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; and confidence intervals 95%, alpha level 0.05.
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![Nfix Is Expressed by SCs and Its Absence Leads to a Reduced Myofiber Cross Sectional Area and to an Increased Slow MyHC Expression\
(A) Immunofluorescence analysis of Nfix expression (green) in Pax7^+^ SCs (red) on a *Tibialis anterior* muscle section of a *Mlc3f-lacz* mouse, where myonuclei are in purple (β-gal). Hoechst was used to stain nuclei (n = 4 mice). The scale bar represents 25 μm.\
(B) H&E staining on *Tibialis anterior* muscles from WT and *Nfix*-null mice (n = 5 mice). The scale bar represents 100 μm.\
(C) Graphical representation of the myofiber cross sectional area (CSA) in WT and *Nfix*-null muscles. The plotted values represent the distribution of n = 65 measurements on five random microscope fields (^∗∗∗^p \< 0.001 and two-tailed unpaired t test). The data are presented as mean ± whiskers from min to max.\
(D) Western blot analysis of slow MyHC expression in WT and *Nfix*-null *Soleus* (SOL) and EDL muscles. The β-tubulin was used to normalize.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![SCs Lacking Nfix Are Characterized by a Delayed Differentiation\
(A) Immunofluorescence analysis of MyoD (green) and Myogenin (Myog, red) expression on single muscle fibers from WT and *Nfix*-null muscles after 24, 48, 72, and 96 hr in culture. Hoechst was used to stain nuclei (n = 3 WT and 3 *Nfix*-null mice). The scale bar represents 50 μm.\
(B) Quantification of MyoD^+^/Myogenin^+^ and MyoD^+^/Myogenin^−^ SCs associated with WT and *Nfix*-null myofibers at 24, 48, 72, and 96 hr in culture. The quantification is the result of three independent experiments on three WT and three *Nfix*-null mice. The data are presented as mean ± SD (not significant, ns; ^∗∗∗^p \< 0.001 with n = 11 WT myofibers and n = 16 *Nfix*-null myofibers; and two-tailed unpaired t test).\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Absence of Nfix Leads to a Marked Impairment of Muscle Regeneration after Injury\
(A) Immunofluorescence for dMHC (green) on regenerating WT and *Nfix*-null *Tibialis anterior* muscles 5, 7, 10, 14, and 28 days (d) following CTX injection. The laminin is marked in red and Hoechst was used to stain nuclei (n = 3 mice for each group). The scale bar represents 50 μm.\
(B) Western blot analysis of Myogenin and Myostatin expression on WT and *Nfix*-null muscles 3, 5, 10, and 28 days (d) following CTX injection. The β-tubulin was used to normalize.\
(C) Western blot analysis of pSmad3 and Smad3 expression on WT and *Nfix*-null muscles 5 and 7 days (d) following CTX injection. GAPDH was used to normalize.\
(D) Quantification of the percentage of dMHC positive myofibers in WT and *Nfix*-null mice after 7 and 14 days following CTX injection (n = 6 mice for time point 7 and n = 5 mice for time point 14). The data are presented as mean ± SD (^∗^p \< 0.05; ^∗∗^p \< 0.01; and two-tailed unpaired t test).\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}E.](gr3){#fig3}

![Absence of Nfix in SCs Determines the Delay in Muscle Regeneration\
(A) H&E staining and immunofluorescence for dMHC (green) on transverse sections of regenerating *Tibialis anterior* muscles from *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*+/+*^ and *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^mice with (TMX) or without (NO TMX) tamoxifen treatment. The muscles were collected and stained after 5, 7, and 14 days (d) from CTX injection. The laminin is marked in red and Hoechst was used to stain nuclei (n = 3 mice for each group). The scale bar represents 100 μm.\
(B) Western blot analysis of Myogenin expression on regenerating muscles from *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*+/+*^ (*Nfix*^*+/+*^) and *Tg:Pax7-Cre*^*ERT2*^*:Nfix*^*fl/*−^ mice (*Nfix*^*fl/*−^) with (TMX) or without (NO TMX) tamoxifen treatment after 3, 5, 7, and 14 days (d) from CTX injection. Myogenin and GAPDH in the right panel come from two separate gels but using the same samples and protein amount. GAPDH was used to normalize.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Nfix Regulates Myostatin Expression in Differentiating Myoblasts through a Direct Binding to its Promoter\
(A) Real-time qPCR showing Myostatin upregulation in differentiating SC-derived myoblasts. The SCs were isolated by FACS and plated in differentiation medium for a time course analysis from 1 to 3 days (DM1, DM2, and DM3) (n = 4 DM1 WT, n = 2 DM1 *Nfix*-null, n = 5 DM2 WT, n = 3 DM2 *Nfix*-null, n = 4 DM3 WT, and n = 4 DM3 *Nfix*-null). The data are presented as mean ± SD (not significant, ns; ^∗^p \< 0.05; ^∗∗^p \< 0.01; and two-tailed unpaired t test).\
(B) Western blot analysis of Nfix expression in C2C12 myoblasts transduced with a control vector (C2C12 scramble) or with a vector carrying a shRNA targeting Nfix (C2C12 shNfix). GAPDH was used to normalize.\
(C) Real-time qPCR analysis of Myostatin expression in scramble and shNfix C2C12 in a time course from 3 to 7 days in differentiation medium. The values are plotted as relative expression and normalized to GAPDH (n = 3 independent samples for each time point). The data are presented as mean ± SD (not significant, ns; ^∗^p \< 0.05; ^∗∗^p \< 0.01; and two-tailed unpaired t test).\
(D) ChIP on differentiated C2C12 transduced with a vector expressing a HA-tagged Nfix2 isoform to test binding to putative Nfix binding sites on Myostatin promoter located at −87/−212 bp and −274/−548 bp from transcription start site. Binding on Nfatc4 promoter and on an intergenic region were used as positive and negative controls, respectively. The data are means of two independent experiments and expressed as fold enrichment (mean ± SD) relative to the IgG signal (n = 3 independent ChIP).\
(E) Real-time qPCR for Myostatin in WT and *Nfix*-null SC-derived myoblasts transduced with a control vector (scramble) or with a vector overexpressing the Nfix2 isoform (Nfix2-HA). The values are plotted as relative expression and normalized to GAPDH (n = 3 samples for each group). The data are presented as mean ± SD (^∗^p \< 0.05; ^∗∗^p \< 0.01; and two-tailed unpaired t test).](gr5){#fig5}

![In Vivo Silencing of Myostatin in Regenerating *Nfix* Null Muscles Rescues their Regeneration Defects\
(A) Immunofluorescence analysis of dMHC expression (green) on regenerating WT and *Nfix*-null *Tibialis anterior* muscles after muscle electroporation with a control plasmid (scramble) or with a plasmid carrying an shRNA targeting Myostatin (shmstn). The muscles were electroporated after 4 days following CTX injection and were collected and stained after 7, 10, and 14 days (d) following CTX injection. The laminin is marked in red and Hoechst was used to stain nuclei (n = 3 mice for each group). The scale bar represents 100 μm.\
(B) Quantification of the percentage of dMHC positive myofibers in *Nfix*-null mice electroporated with scramble or shmstn plasmids after 7 and 14 days following CTX injection (n = 5 mice for each group). The data are presented as mean ± SD (^∗^p \< 0.05 and two-tailed unpaired t test).\
(C) Real-time qPCR showing Myostatin expression in myoblasts re-isolated from *Tibialis anterior* electroporated with control (scramble) or shMyostatin (shMstn) plasmids. The myoblasts were isolated the day after in vivo transfection, and cultures were stopped 2 days later to perform qRT-PCR. The data are presented as mean ± SD.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}
